Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$68.71 USD
-2.51 (-3.52%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $68.70 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Cidara Therapeutics, Inc.'s return on equity, or ROE, is -50.82% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that CDTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CDTX 68.71 -2.51(-3.52%)
Will CDTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Other News for CDTX
Cidara's Flu Drug: A Phase 2 Triumph, A Phase 3 Gauntlet
CDTX makes New 52 Week High on September 19
CDTX makes New 52 Week Closing High on September 18
Is CDTX likely to continue higher? 20 Day Moving Average Support shows up after rising 0.22%
Cidara Therapeutics (CDTX) Unveils Promising Data on Influenza Drug at ISRV Conference